Skip to main content
Premium Trial:

Request an Annual Quote

With an Eye on Future Array Development, Invitrogen Licenses Affymetrix s Patents

Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix's micorarray patents, the firms announced this week.

Invitrogen is being tight-lipped about which patents it has licensed from Affymetrix and whether it intends to expand into the field of DNA microarrays, but it is clear the firm intends to expand its franchise in the non-coding RNA tools market.

"This was an opportunity for us to bring in some capabilities through additional intellectual property," said Greg Geissman, an Invitrogen spokesman.

Under the agreement, Invitrogen is allowed to "manufacture and sell spotted nucleic acid microarrays in the research field," the companies said. Financial details of the license were not disclosed.

Over the past few years, Invitrogen has played on the periphery of the microarray market, primarily as a provider of oligonucleotides, and the firm has supplied reagents to Affymetrix for some of its chips. But its presence in the field is growing.

Late last year, Invitrogen, along with partner Illumina, launched new tube-based oligos that enable researchers to buy twice as much primer for the same price as they previously paid for the same product. Invitrogen's ability to offer the oligos at that price is due to efficiencies at Illumina's manufacturing facility, which Illumina executed using Invitrogen's $3.4-million investment (see BioCommerce Week 12/23/2004).

"We're not concerned about OGT or anyone else. We have a variety of licenses which give us freedom to operate in this space."

The firm also sells protein arrays and recently introduced its NCode microRNA microarray platform. The platform consists of a miRNA isolation product, a labeling and detection system, an array for profiling microRNA-expression patterns, and some controls.

"We have the availability to develop array products and, at the present time, the arrays that we are focusing on developing are in the area of epigenetics," Amy Butler, vice president of gene expression profiling for Invitrogen, told BioCommerce Week. "We have plans to develop additional arrays in the [non-coding RNA] field in the not-too-distant future."

The firm is competing directly in the emerging miRNA market with Applied Biosystems and GE Healthcare, which both launched miRNA arrays late last year. But unlike these competitors, Invitrogen does not offer any instrumentation.

Though research on microRNAs has been going on for at least a couple of decades, it remains a nascent field with potential applications in identifying biomarkers for cancer, stem cell research, and developmental biology.

The miRNAs fit in with Invitrogen's plans for developing biomarkers for the molecular diagnostics market, Peter Jozsi, Invitrogen's manager for NCode, told BioCommerce Week last November (see BioCommerce Week 11/17/2005). "We are already evaluating and have some interesting results in-house using these arrays to profile stem cells," he said.

Asked this week whether the licenses cover DNA microarrays, Butler replied, "I can't comment on the specifics of the agreement."

She also would not say if Invitrogen had taken a license from Oxford Gene Technology, which holds a broad-based microarray technology patent and has launched several lawsuits against competitors in the field.

"Invitrogen has all the licenses it needs currently for the products it now has," said Butler. "I don't want to officially list what all those agreements are, but we're not concerned about OGT or anyone else. We have a variety of licenses which give us freedom to operate in this space," she said.

The licensing deal is the third in seven months for Affymetrix, which is the dominant player in the microarray market for gene expression applications. In April, the microarray company licensed patents to Abbott Laboratories to enable it to manufacture and sell comparative genomic hybridization microarrays, readers, and software for research and diagnostics.

Last December, Affymetrix licensed an undisclosed number of patents to ABI related to the manufacture, sale, and use of microarrays for gene expression analysis. ABI is a distant third in the microarray market for gene expression applications, trailing Affymetrix and BCW Index rival Agilent.

— Edward Winnick ([email protected])

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.